Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Sensitivity and Specificity

imatinib mesylate has been researched along with Sensitivity and Specificity in 109 studies

Research

Studies (109)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's75 (68.81)29.6817
2010's32 (29.36)24.3611
2020's2 (1.83)2.80

Authors

AuthorsStudies
Bence-Bruckler, I; Busque, L; Cote, Y; Hamm, C; Hasegawa, W; Hillis, CM; Jackson Chornenki, NL; Kamel-Reid, S; Leber, B; Lipton, JH; Savoie, L; Turner, AR; Xenocostas, A1
Beijnen, JH; Lucas, L; Roosendaal, J; Rosing, H; Venekamp, N1
Hang, T; Qiang, S; Wen, A; Xu, Z; Yang, L; Yu, Z; Zhang, W; Zhang, Y1
Černelč, P; Kralj, E; Kristl, A; Marc, J; Ostanek, B; Pajič, T; Preložnik Zupan, I; Trontelj, J; Žakelj, S1
Bendit, I; de Alencar Fisher Chamone, D; Novaes, MM; Rezende, VM; Rivellis, A1
Fujito, H; Saita, T; Shin, M1
Akard, LP; Albitar, M; Cortes, JE; Ericson, SG; Goldberg, SL; Radich, JP; Warsi, G; Wetzler, M1
Baerlocher, GM; Dengler, J; Dietz, C; Einsele, H; Erben, P; Fabarius, A; Falge, C; Hänel, M; Hanfstein, B; Hasford, J; Hehlmann, R; Hochhaus, A; Hofmann, WK; Kanz, L; Kneba, M; Krause, SW; Lauseker, M; Müller, MC; Neubauer, A; Pfirrmann, M; Pfreundschuh, M; Proetel, U; Saussele, S; Schnittger, S; Schubert, J; Shlyakhto, V; Spiekermann, K; Stegelmann, F; Waller, CF1
Alikian, M; Alonso-Dominguez, JM; Apperley, J; Clark, RE; Daghistani, M; Foroni, L; Gerrard, G; Grinfeld, J; Hedgley, C; Marin, D; O'Brien, S; Reid, A1
Graziani, R; Guindani, M; Thall, PF1
Boglione, A; Comandone, A1
Baldini, C; Bridal, SL; Comperat, E; Dizeux, A; Lamuraglia, M; Le Guillou-Buffello, D; Lucidarme, O; Payen, T1
Abo, M; Hara, J; Kasahara, K; Kimura, H; Nakao, S; Nishikawa, S; Sone, T; Takato, H; Waseda, Y; Watanabe, S; Yoneda, T1
Ha, HK; Kim, AY; Kim, HJ; Kim, JS; Lee, JS; Park, SH1
Bantscheff, M; Boesche, M; Eberhard, D; Kuster, B; Matthieson, T; Sweetman, G1
Baeumler, J; Falkenburg, JH; Nijmeijer, BA; Ottmann, OG; Szuhai, K; van Schie, ML1
Albiter, M; Bonvalot, S; Dromain, C; Le Cesne, A; Le Péchoux, C; Mabille, M; Shapeero, LG; Terrier, P; Vanel, D1
Dietrich, C; Hartung, E; Ignee, A1
Duncan, C; Galviz, G; Hsieh, Y; Zhou, Q1
Baietto, L; D'Avolio, A; De Francia, S; De Martino, F; Di Carlo, F; Di Perri, G; Pirro, E; Racca, S; Saglio, G; Siccardi, M; Simiele, M1
Cortes, J; Jabbour, E; Jones, D; Kantarjian, HM; O'Brien, S; Rios, MB; Shan, J1
Kurtaran, A; Schima, W1
Awidi, A; Mefleh, R; Najib, N; Salem, II; Tarawneh, B1
Clark, RE; Davies, A; Hayes, AK; Knight, K; Pirmohamed, M; Watmough, SJ1
DU, QF; Liu, XL; Meng, FY; Zhang, S1
Oehler, VG; Radich, JP1
Apperley, JF; Cross, NC; Melo, JV; Score, J; Sobrinho-Simões, M; Wilczek, V1
Bartley, PA; Branford, S; Budgen, B; Hughes, TP; Latham, S; Martin-Harris, MH; Morley, AA; Ross, DM; Wilczek, V1
Asaka, M; Darmanin, S; Kondo, T; Mizutani, T; Ohba, Y; Tanaka, S; Tobiume, M; Tsuda, M1
Arthur, C; Bartley, PA; Branford, S; Dang, P; Field, C; Filshie, RJ; Grigg, AP; Hughes, TP; Melo, JV; Mills, AK; Ross, DM; Schwarer, AP; Seymour, JF; Slader, C1
Ayuso, JR; Casado, A; Cubedo, R; Del Muro, XG; Fuster, D; Lomeña, F; López-Pousa, A; Martínez-Trufero, J; Maurel, J; Pons, F; Poveda, A1
Guenther, S; Römpp, A; Spengler, B; Takats, Z1
Miura, M; Sawada, K; Takahashi, N1
Ajimura, TO; Borges, KB; de Castro, FA; de Gaitani, CM; Ferreira, AF1
Elliott, M; Holyoake, T; Iqbal, Z; Jørgensen, H; Watson, DG1
Ankathil, R; Gan, SH; Tan, KL1
Huang, L; Huang, Y; Li, J; Xiang, G; Xu, L; Ye, L; Zhou, Z1
Chu, YC; Gong, NJ; Gu, J; Wong, CS1
Kralj, E; Kristl, A; Pajič, T; Trontelj, J1
Birch, M; Flanagan, RJ; Handley, S; Ho, A; Ireland, R; Morgan, PE1
Gallowitsch, HJ; Malle, P; Sorschag, M1
Ansah, AJ; Bamdad, M; Berger, J; Berger, MG; Boiret-Dupré, N; Bourgne, C; Cahn, JY; Gagnieu, MC; Guerci, A; Guyotat, D; Hermet, E; Janel, A; Libert, F; Makhoul, PC; Pereira, B; Pereira, S; Pigeon, P; Rapatel, C; Trouillier, S1
Arellano, C; Chatelut, E; Gandia, P; Jongejan, R; Lafont, T1
Berger, U; Gschaidmeier, H; Hehlmann, R; Hochhaus, A; Kreil, S; Kuhn, C; Lahaye, T; Merx, K; Müller, MC; Paschka, P; Schoch, C; Weisser, A1
Elcock, AH; Rockey, WM1
Ashman, LK; Ferrao, PT; Frost, MJ; Hughes, TP1
Antonescu, C; Brennan, MF; Dematteo, RP; Maki, RG1
Alyea, EP; Capdeville, R; Chillemi, A; DeAngelo, D; Galinsky, I; Hochberg, EP; McLaughlin, S; Neuberg, D; Ritz, J; Soiffer, RJ; Stone, RM; Wu, CJ1
Dörken, B; Hochhaus, A; Kreuzer, KA; Landt, O; Le Coutre, P; Na, IK; Schultheis, K; Schwarz, M1
Egorin, MJ; Hayes, MJ; Parise, RA; Ramanathan, RK1
Berger, U; Gschaidmeier, H; Hehlmann, R; Hochhaus, A; König, H; Kreil, S; Lahaye, T; Merx, K; Müller, MC; Paschka, P; Petzold, A; Schoch, C; Weisser, A1
Deininger, MW; Lange, T; Niederwieser, DW1
Bergemann, T; Bonin, M; Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Gruner, M; Gschaidmeier, H; Jenke, A; Köhne, CH; le Coutre, P; Leopold, T; Ottmann, OG; Pursche, S; Renner, U; Schleyer, E; Schuler, U1
De Boeck, G; de Bruijn, EA; Dumez, H; Guetens, G; Highley, M; Van Oosterom, AT1
Gayed, I; Iyer, R; Johnson, M; Macapinlac, H; Podoloff, D; Swanston, N; Vu, T1
Bainbridge, TM; Deininger, MW; Druker, BJ; Heinrich, MC; McGreevey, L; Willis, S1
Antoch, G; Bauer, S; Bockisch, A; Debatin, JF; Freudenberg, LS; Kanja, J; Kuehl, H; Renzing-Koehler, K; Schuette, J1
Béguin, A; Biollaz, J; Buclin, T; Decosterd, LA; Duchosal, MA; Kovacsovics, T; Leyvraz, S; Rochat, B; Rosselet, A; Widmer, N1
Agarwal, NK; Arora, B; Gupta, SK; Kumar, L; Mathur, R; Velpandian, T1
Gietema, JA; Jager, PL; van der Graaf, WT1
Amabile, M; Baccarani, M; Bianchini, M; Martinelli, G; Pane, F; Poerio, A; Rosti, G; Saglio, G; Soverini, S1
Bronk, SF; Chiorean, MV; Gores, GJ; Guicciardi, ME; Kaufmanns, SH; Yoon, JH1
Goldman, J1
Allen, TJ; Calkin, AC; Cooper, ME; Jandeleit-Dahm, K; Lassila, M; Seah, KK; Smith, CM1
Attard, G; De Bono, J; Kaye, S; Vidal, L1
Barghouth, G; Dizendorf, E; Goerres, GW; Hany, TF; Leyvraz, S; Luthi, F; Pestalozzi, B; Schnyder, P; Stupp, R; von Schulthess, GK1
Berzas Nevado, JJ; Cabello Díaz, MP; Contento Salcedo, AM; Rodríguez-Flores, J1
Crossman, L; Deininger, MW; Demehri, S; Druker, BJ; Kovacs, I; Lange, T; McWeeney, S; Niederwieser, D; Otto, S; Park, B; Stoffregen, EP; Willis, SG1
Desplat, V; Lagarde, V; Leguay, T; Mahon, FX; Marit, G; Reiffers, J1
De Wever, I; Debiec-Rychter, M; Pauwels, P; Sciot, R; Stul, M; Van Oosterom, AT1
Chmelik, P; Felix, R; Gaffke, G; Hohenberger, P; Jost, D; Kretzschmar, A; Reichardt, P; Schneider, U; Stroszczynski, C1
Cortes, J; Kantarjian, H1
Berthaud, P; Ducint, D; Mahon, FX; Molimard, M; Moore, N; Picard, S; Teilhet, E; Titier, K1
Frantz, S1
Deininger, MW; Lange, T; Park, B; Willis, SG1
Dumur, CI; Ferreira-Gonzalez, A; Fossey, SC; Garrett, CT; Vnencak-Jones, CL1
Al-Jabary, T; Anand, M; Apperley, JF; Goldman, JM; Iqbal, A; Kaeda, J; Khorashad, JS; Margerison, S; Marin, D; Melo, JV; Saunders, S1
Branford, S; Hughes, TP; Moore, S; Ross, DM1
Buxhofer-Ausch, V; Hinterberger, W; Hinterberger-Fischer, M1
Cotter, TG; Hickey, FB1
Cross, NC; Curtis, C; Grand, FH; Jotterand, M; Score, J; Stalder, M; Waghorn, K1
Boultwood, J; Campbell, LJ; Eagleton, H; Fidler, C; Gal, S; Kusec, R; Littlewood, TJ; Peniket, A; Wainscoat, JS1
Copland, M; Elrick, L; Hamilton, A; Holyoake, T; Jørgensen, H; Melo, JV; Myssina, S1
Corbin, AS; Dent, P; Druker, BJ; Gao, N; Grant, S; Kramer, L; Nguyen, TK; Rahmani, M1
Goh, HG; Hwang, JY; Kang, HY; Kim, DW; Kim, M; Kim, SH1
Dirnhofer, S; Went, P; Zimpfer, A1
Musmade, P; Subramanian, G; Vadera, N1
Albitar, M; Bhalla, K; Giles, F; Gorre, M; Jilani, I; Kantarjian, H; Ma, W; Ottmann, O1
De Boeck, G; de Bruijn, EA; Guetens, G; Highley, M; Prenen, H; Schöffski, P; van Oosterom, A1
Bainbridge, T; Corless, CL; Gatter, K; Granter, S; Harrell, P; Heinrich, MC; Lacouture, M; Le, C; White, C1
Bidoli, P; Casali, PG; Casieri, P; Miselli, F; Negri, T; Orsenigo, M; Piacenza, C; Pierotti, MA; Pilotti, S; Stacchiotti, S; Tamborini, E1
Bielejewska, A; Kosmacińska, B; Rozmarynowska, D; Skarzyński, M; Szczepek, WJ; Łuniewski, W1
Beijnen, JH; Oostendorp, RL; Schellens, JH; Tellingen, Ov1
Chang, BS; Cibas, ES; Fletcher, JA; Yang, T1
Benjamin, RS; Burgess, MA; Charnsangavej, C; Chen, LL; Choi, H; Faria, SC; Macapinlac, HA; Patel, SR; Podoloff, DA1
Benjamin, RS; Burgess, MA; Charnsangavej, C; Chen, LL; Choi, H; Macapinlac, HA; Patel, SR; Podoloff, DA1
Aksenova, EV; Chelysheva, EIu; Domracheva, EV; Khoroshko, ND; Misiurin, AV; Turkina, AG; Zakharova, AV1
Branford, S; Hughes, TP; Nicoll, JM; Paquette, RL; Sawyers, CL; Shah, NP; Skaggs, BJ1
Agis, H; Esterbauer, H; Geissler, K; Haas, OA; Herndlhofer, S; Jäger, U; Mannhalter, C; Pirc-Danoewinata, H; Semper, H; Sillaber, C; Sperr, WR; Valent, P1
de Jong, FA; Gietema, JA; Perik, PJ; Rikhof, B; van der Graaf, WT; Verweij, J1
Badawi, RD; Demetri, GD; Holdsworth, CH; Israel, DA; Kijewski, MF; Manola, JB; Van den Abbeele, AD1
Arthur, C; Branford, S; Grigg, A; Hughes, T; Lynch, K; Rudzki, Z; Seymour, JF1
Albitar, M; Bhalla, K; Cortes, J; Faraji, H; Giles, F; Gorre, M; Jilani, I; Kantarjian, H; O'Brien, S; Ottmann, O1
Kim, MA; Kim, WH; Lee, BL; Lee, HE; Lee, HS1
Scheinberg, DA1
Dimitrijevic, S; Joensuu, H1
Bakhtiar, R; Hayes, M; Khemani, L; Lohne, J; Ramos, L; Tse, F1
Druker, BJ; O'Dwyer, ME1
Buchdunger, E; Corbin, AS; Druker, BJ; Pascal, F1

Reviews

8 review(s) available for imatinib mesylate and Sensitivity and Specificity

ArticleYear
Monitoring BCR-ABL in the treatment of chronic myeloid leukemia by polymerase chain reaction.
    Current hematologic malignancy reports, 2006, Volume: 1, Issue:3

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Bone Marrow Transplantation; Child; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Drug Monitoring; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Sensitivity and Specificity

2006
FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours.
    Wiener medizinische Wochenschrift (1946), 2012, Volume: 162, Issue:19-20

    Topics: Antineoplastic Agents; Benzamides; Blood Glucose; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Multimodal Imaging; Neoplasm Recurrence, Local; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Pyrroles; Sensitivity and Specificity; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome

2012
Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor.
    Current problems in surgery, 2003, Volume: 40, Issue:3

    Topics: Benzamides; Biopsy, Needle; Chemotherapy, Cancer, Regional Perfusion; Enzyme Inhibitors; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunohistochemistry; Liver Neoplasms; Male; Neoplasm Staging; Peritoneal Neoplasms; Piperazines; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Stromal Cells; Survival Analysis; Treatment Outcome

2003
Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era.
    Current opinion in hematology, 2005, Volume: 12, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm, Residual; Piperazines; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Sensitivity and Specificity; WT1 Proteins

2005
Reversing resistance to targeted therapy.
    Journal of chemotherapy (Florence, Italy), 2004, Volume: 16 Suppl 4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Imatinib Mesylate; Male; Neoplasms; Piperazines; Pyrimidines; Quinazolines; Risk Assessment; Sensitivity and Specificity; Trastuzumab

2004
New targeted approaches in chronic myeloid leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Sep-10, Volume: 23, Issue:26

    Topics: Benzamides; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Prognosis; Pyrimidines; Sensitivity and Specificity; Severity of Illness Index; Survival Analysis

2005
Old, new drugs and new, new drugs for the new millennium.
    Current oncology reports, 2000, Volume: 2, Issue:2

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Clinical Trials as Topic; Female; Forecasting; Humans; Imatinib Mesylate; Leukemia, Promyelocytic, Acute; Male; Oxides; Piperazines; Prognosis; Pyrimidines; Sensitivity and Specificity; Treatment Outcome

2000
STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.
    The Lancet. Oncology, 2000, Volume: 1

    Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Disease Models, Animal; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sensitivity and Specificity

2000

Trials

14 trial(s) available for imatinib mesylate and Sensitivity and Specificity

ArticleYear
Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study.
    Archives of pathology & laboratory medicine, 2014, Volume: 138, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biopsy; Bone Marrow; Cytogenetic Analysis; Dose-Response Relationship, Drug; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Molecular Diagnostic Techniques; Piperazines; Pyrimidines; Sensitivity and Specificity; Severity of Illness Index; Time Factors; Treatment Outcome

2014
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.
    Leukemia, 2014, Volume: 28, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Glucuronidase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Proportional Hazards Models; Pyrimidines; Risk; Sensitivity and Specificity; Treatment Outcome; Young Adult

2014
Bayesian nonparametric estimation of targeted agent effects on biomarker change to predict clinical outcome.
    Biometrics, 2015, Volume: 71, Issue:1

    Topics: Antineoplastic Agents; Bayes Theorem; Biomarkers; Data Interpretation, Statistical; Epidemiologic Methods; Humans; Imatinib Mesylate; Male; Molecular Targeted Therapy; Outcome Assessment, Health Care; Prognosis; Prostatic Neoplasms; Reproducibility of Results; Sensitivity and Specificity; Survival Analysis

2015
Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!).
    European journal of radiology, 2009, Volume: 69, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Piperazines; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome

2009
Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study.
    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2011, Volume: 55, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Spain; Treatment Outcome

2011
Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS.
    Pakistan journal of pharmaceutical sciences, 2011, Volume: 24, Issue:3

    Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Chromatography, Liquid; Drug Stability; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Limit of Detection; Piperazines; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Spectrometry, Mass, Electrospray Ionization

2011
Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Leukemia, 2002, Volume: 16, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Marrow; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity; Survival Rate

2002
The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2004, Volume: 45, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Benzamides; False Positive Reactions; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; Radiography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic; Stromal Cells; Tomography, Emission-Computed; Treatment Outcome

2004
Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2004, Volume: 45, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Stromal Cells; Subtraction Technique; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome

2004
Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.
    Nuclear medicine communications, 2004, Volume: 25, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Radiopharmaceuticals; Reproducibility of Results; Sarcoma; Sensitivity and Specificity; Treatment Outcome

2004
The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
    European journal of nuclear medicine and molecular imaging, 2005, Volume: 32, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Longitudinal Studies; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Survival Analysis; Switzerland; Tomography, X-Ray Computed; Treatment Outcome

2005
Follow-up of gastro-intestinal stromal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI.
    European radiology, 2005, Volume: 15, Issue:12

    Topics: Abdomen; Adult; Aged; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome

2005
CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.
    AJR. American journal of roentgenology, 2007, Volume: 189, Issue:6

    Topics: Antineoplastic Agents; Benzamides; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Pilot Projects; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome; United States

2007
BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict se
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Dec-01, Volume: 13, Issue:23

    Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Mutation; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction; RNA, Messenger; Sensitivity and Specificity

2007

Other Studies

87 other study(ies) available for imatinib mesylate and Sensitivity and Specificity

ArticleYear
The predictive value of intracellular imatinib levels in newly diagnosed chronic myeloid leukemia.
    Leukemia research, 2020, Volume: 88

    Topics: Biological Availability; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Leukemic; Genes, abl; Humans; Imatinib Mesylate; Intracellular Space; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Octamer Transcription Factor-1; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Treatment Outcome

2020
Development and validation of an LC-MS/MS method for the quantification of imatinib and imatinib-d8 in human plasma for the support of an absolute bioavailability microdose trial.
    Die Pharmazie, 2020, 04-06, Volume: 75, Issue:4

    Topics: Biological Availability; Chromatography, High Pressure Liquid; Humans; Imatinib Mesylate; Limit of Detection; Mass Spectrometry; Protein Kinase Inhibitors; Reproducibility of Results; Sensitivity and Specificity

2020
LC-MS-MS determination of imatinib and N-desmethyl imatinib in human plasma.
    Journal of chromatographic science, 2014, Volume: 52, Issue:4

    Topics: Adult; Benzamides; Chromatography, High Pressure Liquid; Humans; Imatinib Mesylate; Linear Models; Male; Piperazines; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry

2014
Monitoring of imatinib targeted delivery in human leukocytes.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2013, Sep-27, Volume: 50, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Granulocytes; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Limit of Detection; Piperazines; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry

2013
Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays.
    Drug design, development and therapy, 2013, Volume: 7

    Topics: Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Stability; Humans; Imatinib Mesylate; Mass Spectrometry; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity

2013
Development of a specific and sensitive enzyme-linked immunosorbent assay for the quantification of imatinib.
    Biological & pharmaceutical bulletin, 2013, Volume: 36, Issue:12

    Topics: Animals; Antibodies; Benzamides; Drug Monitoring; Enzyme-Linked Immunosorbent Assay; Female; Horseradish Peroxidase; Humans; Imatinib Mesylate; Mice; Mice, Inbred BALB C; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Rabbits; Sensitivity and Specificity; Serum Albumin, Bovine

2013
PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase.
    American journal of hematology, 2015, Volume: 90, Issue:1

    Topics: Benzamides; Cohort Studies; Disease-Free Survival; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Profiling; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Patched Receptors; Patched-1 Receptor; Pilot Projects; Piperazines; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Receptors, Cell Surface; Sensitivity and Specificity; Transcriptome; Treatment Failure

2015
[The importance of mutational status in prognosis and therapy of GIST].
    Recenti progressi in medicina, 2015, Volume: 106, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Phenylurea Compounds; Piperazines; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sensitivity and Specificity; Sunitinib

2015
VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
    Ultrasound in medicine & biology, 2015, Volume: 41, Issue:8

    Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Survival; Contrast Media; Drug Monitoring; Female; Imatinib Mesylate; Indoles; Mice; Mice, Inbred BALB C; Molecular Imaging; Neoplasms, Experimental; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Treatment Outcome; Ultrasonography; Vascular Endothelial Growth Factor Receptor-2

2015
Imatinib ameliorates bronchiolitis obliterans via inhibition of fibrocyte migration and differentiation.
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2017, Volume: 36, Issue:2

    Topics: Animals; Biopsy, Needle; Bronchiolitis Obliterans; Cell Differentiation; Cell Movement; Cells, Cultured; Disease Models, Animal; Fibroblasts; Imatinib Mesylate; Immunohistochemistry; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Random Allocation; Sensitivity and Specificity; Statistics, Nonparametric

2017
Computed tomography features and predictive findings of ruptured gastrointestinal stromal tumours.
    European radiology, 2017, Volume: 27, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Ascites; Disease Progression; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hematoma; Hemoperitoneum; Humans; Imatinib Mesylate; Indoles; Intestine, Small; Male; Middle Aged; Necrosis; Peritonitis; Pyrroles; Rupture, Spontaneous; Sensitivity and Specificity; Sunitinib; Tomography, X-Ray Computed; Young Adult

2017
Robust and sensitive iTRAQ quantification on an LTQ Orbitrap mass spectrometer.
    Molecular & cellular proteomics : MCP, 2008, Volume: 7, Issue:9

    Topics: Benzamides; Cell Line, Tumor; Humans; Imatinib Mesylate; Isotope Labeling; Jurkat Cells; Peptides; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Pyrimidines; Sensitivity and Specificity; Tandem Mass Spectrometry

2008
Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement.
    Cancer genetics and cytogenetics, 2008, Volume: 185, Issue:1

    Topics: Adult; Benzamides; Cell Line, Tumor; Cell Survival; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 6; Cytogenetic Analysis; Dose-Response Relationship, Drug; Genes, abl; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Sensitivity and Specificity; Translocation, Genetic

2008
The use of contrast-enhanced ultrasound in patients with GIST metastases that are negative in CT and PET.
    Ultraschall in der Medizin (Stuttgart, Germany : 1980), 2008, Volume: 29 Suppl 5

    Topics: Adult; Antineoplastic Agents; Benzamides; Contrast Media; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Ultrasonography

2008
Hydrophilic interaction liquid chromatography/tandem mass spectrometry for the simultaneous determination of dasatinib, imatinib and nilotinib in mouse plasma.
    Rapid communications in mass spectrometry : RCM, 2009, Volume: 23, Issue:9

    Topics: Animals; Benzamides; Chromatography, Liquid; Dasatinib; Imatinib Mesylate; Linear Models; Mice; Piperazines; Pyrimidines; Sensitivity and Specificity; Tandem Mass Spectrometry; Thiazoles

2009
New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2009, Jun-15, Volume: 877, Issue:18-19

    Topics: Antineoplastic Agents; Benzamides; Calibration; Chromatography, High Pressure Liquid; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mass Spectrometry; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sensitivity and Specificity; Thiazoles

2009
Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-01, Volume: 27, Issue:22

    Topics: Benzamides; Cause of Death; Cohort Studies; Cytogenetics; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Probability; Protein Kinase Inhibitors; Pyrimidines; Sensitivity and Specificity; Severity of Illness Index; Survival Analysis; Time Factors; Treatment Outcome

2009
[GIST: Imaging diagnosis, staging, and response assessment].
    Wiener medizinische Wochenschrift (1946), 2009, Volume: 159, Issue:15-16

    Topics: Antineoplastic Agents; Benzamides; Biopsy; Colonic Neoplasms; Contrast Media; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Image Processing, Computer-Assisted; Imatinib Mesylate; Liver Neoplasms; Neoplasm Staging; Piperazines; Positron-Emission Tomography; Pyrimidines; Sensitivity and Specificity; Stomach Neoplasms; Tomography, Spiral Computed

2009
Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: methods' comparison.
    Leukemia research, 2010, Volume: 34, Issue:6

    Topics: Adult; Antineoplastic Agents; Benzamides; Blood Chemical Analysis; Calibration; Chromatography, High Pressure Liquid; Chromatography, Liquid; Circadian Rhythm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tandem Mass Spectrometry

2010
Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography.
    Leukemia research, 2010, Volume: 34, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blood Chemical Analysis; Calibration; Chromatography, High Pressure Liquid; Circadian Rhythm; Humans; Imatinib Mesylate; Limit of Detection; Piperazines; Plasma; Protein Kinase Inhibitors; Pyrimidines; Quality Control; Sensitivity and Specificity; Spectrophotometry, Ultraviolet

2010
[Dual-color/dual-fusion interphase fluorescence in situ hybridization probe for monitoring tumor load during imatinib therapy for chronic myeloid leukemia].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2010, Volume: 30, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Female; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interphase; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Sensitivity and Specificity; Tumor Burden; Young Adult

2010
In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib.
    Blood, 2010, Aug-26, Volume: 116, Issue:8

    Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Stem Cell Transplantation; Young Adult

2010
Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA.
    International journal of laboratory hematology, 2010, Volume: 32, Issue:6 Pt 1

    Topics: Antineoplastic Agents; Benzamides; DNA, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity

2010
A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Aug-01, Volume: 16, Issue:15

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Benzamides; Biosensing Techniques; Blotting, Western; Cell Separation; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescence Resonance Energy Transfer; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Luminescent Agents; Nuclear Proteins; Phosphorylation; Piperazines; Pyrimidines; Sensitivity and Specificity

2010
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.
    Leukemia, 2010, Volume: 24, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; DNA, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction; Sensitivity and Specificity; Survival Rate; Treatment Outcome

2010
Mass spectrometry imaging with high resolution in mass and space (HR(2) MSI) for reliable investigation of drug compound distributions on the cellular level.
    Analytical and bioanalytical chemistry, 2011, Volume: 401, Issue:1

    Topics: Animals; Antineoplastic Agents; Benzamides; Diagnostic Imaging; Gastrointestinal Tract; Ifosfamide; Imatinib Mesylate; Kidney; Mice; Mice, Nude; Piperazines; Pyrimidines; Rats; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

2011
Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection.
    Journal of chromatographic science, 2011, Volume: 49, Issue:5

    Topics: Benzamides; Chromatography, High Pressure Liquid; Dasatinib; Drug Stability; Humans; Imatinib Mesylate; Linear Models; Piperazines; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Thiazoles

2011
Capillary electrophoresis method for plasmatic determination of imatinib mesylate in chronic myeloid leukemia patients.
    Electrophoresis, 2011, Volume: 32, Issue:14

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Drug Monitoring; Drug Stability; Electrophoresis, Capillary; Female; Humans; Imatinib Mesylate; Least-Squares Analysis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity

2011
Method development and validation for the simultaneous determination of imatinib mesylate and N-desmethyl imatinib using rapid resolution high performance liquid chromatography coupled with UV-detection.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2011, Nov-15, Volume: 879, Issue:30

    Topics: Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Stability; Humans; Hydrogen-Ion Concentration; Imatinib Mesylate; Least-Squares Analysis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet

2011
Determination of imatinib mesylate and related compounds by field amplified sample stacking with large volume sample injection capillary electrophoresis.
    Journal of pharmaceutical and biomedical analysis, 2012, Volume: 70

    Topics: 2-Hydroxypropyl-beta-cyclodextrin; Antineoplastic Agents; Benzamides; beta-Cyclodextrins; Buffers; Drug Contamination; Electrophoresis, Capillary; Hydrogen-Ion Concentration; Hydrolysis; Imatinib Mesylate; Phosphates; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality Control; Reproducibility of Results; Sensitivity and Specificity; Solvents

2012
Treatment response monitoring in patients with gastrointestinal stromal tumor using diffusion-weighted imaging: preliminary results in comparison with positron emission tomography/computed tomography.
    NMR in biomedicine, 2013, Volume: 26, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Diffusion Magnetic Resonance Imaging; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multimodal Imaging; Pilot Projects; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome

2013
Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2012, Aug-15, Volume: 903

    Topics: Benzamides; Chromatography, High Pressure Liquid; Dasatinib; Dried Blood Spot Testing; Drug Stability; Humans; Imatinib Mesylate; Linear Models; Piperazines; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Thiazoles

2012
Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib.
    Biomedical chromatography : BMC, 2013, Volume: 27, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chromatography, High Pressure Liquid; Dasatinib; Drug Monitoring; Female; Hematocrit; Humans; Imatinib Mesylate; Linear Models; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Thiazoles

2013
Measurement of imatinib uptake by flow cytometry.
    Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2012, Volume: 81, Issue:11

    Topics: Antineoplastic Agents; Benzamides; Cell Shape; Culture Media; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Flow Cytometry; Fluorescence; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Sensitivity and Specificity; Ultraviolet Rays

2012
Determination of unbound fraction of imatinib and N-desmethyl imatinib, validation of an UPLC-MS/MS assay and ultrafiltration method.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2012, Oct-15, Volume: 907

    Topics: Adult; Benzamides; Chromatography, High Pressure Liquid; Female; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Ultrafiltration

2012
Progress toward virtual screening for drug side effects.
    Proteins, 2002, Sep-01, Volume: 48, Issue:4

    Topics: Adenosine Diphosphate; Algorithms; Azepines; Benzamides; Binding Sites; Computational Biology; Computer Simulation; Drug Delivery Systems; Enzyme Inhibitors; Guanosine Diphosphate; Imatinib Mesylate; Models, Molecular; Piperazines; Protein Binding; Protein Kinases; Pyrimidines; Pyrroles; Receptors, Drug; Receptors, Purinergic P2; Sensitivity and Specificity; Static Electricity

2002
Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.
    Molecular cancer therapeutics, 2002, Volume: 1, Issue:12

    Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Division; Cell Separation; DNA-Binding Proteins; Flow Cytometry; Genetic Vectors; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imatinib Mesylate; Microscopy, Fluorescence; Mutation; Phosphorylation; Piperazines; Precipitin Tests; Prognosis; Protein Isoforms; Protein Structure, Tertiary; Proto-Oncogene Proteins c-kit; Pyrimidines; Retroviridae; Sensitivity and Specificity; Signal Transduction; STAT3 Transcription Factor; Trans-Activators; Tumor Cells, Cultured

2002
Quantitative monitoring of BCR/ABL transcript during STI-571 therapy.
    Leukemia & lymphoma, 2002, Volume: 43, Issue:12

    Topics: Adult; Aged; Benzamides; Bone Marrow Examination; Cytogenetic Analysis; Drug Monitoring; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; Middle Aged; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity

2002
Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique.
    Annals of hematology, 2003, Volume: 82, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Benzamides; Binding, Competitive; Clone Cells; DNA Probes; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Nucleic Acid Hybridization; Peptide Nucleic Acids; Piperazines; Polymerase Chain Reaction; Pyrimidines; Retrospective Studies; Sensitivity and Specificity

2003
Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2003, Jul-05, Volume: 791, Issue:1-2

    Topics: Benzamides; Chromatography, Liquid; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization

2003
Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Leukemia, 2003, Volume: 17, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity; Survival Rate

2003
Residual disease in chronic myeloid leukemia after induction of molecular remission.
    The New England journal of medicine, 2003, Oct-09, Volume: 349, Issue:15

    Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction; Sensitivity and Specificity

2003
Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2004, Jan-05, Volume: 799, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Culture Media; Electrochemistry; Enzyme Inhibitors; HL-60 Cells; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet

2004
Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry.
    Journal of chromatography. A, 2003, Dec-05, Volume: 1020, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Erythrocytes; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization

2003
Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography.
    Leukemia, 2004, Volume: 18, Issue:4

    Topics: Adult; Aged; Benzamides; Chromatography, High Pressure Liquid; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Oncogene Proteins v-abl; Piperazines; Protein Structure, Tertiary; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity

2004
Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2004, Apr-25, Volume: 803, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet

2004
Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2004, May-25, Volume: 804, Issue:2

    Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Calibration; Chromatography, High Pressure Liquid; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrimidines; Sensitivity and Specificity; Spectrophotometry, Ultraviolet

2004
Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib.
    Clinical chemistry, 2004, Volume: 50, Issue:7

    Topics: Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity

2004
Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells.
    Liver international : official journal of the International Association for the Study of the Liver, 2004, Volume: 24, Issue:6

    Topics: Analysis of Variance; Apoptosis; Benzamides; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Caspases; Cholangiocarcinoma; Epidermal Growth Factor; Female; Humans; Imatinib Mesylate; Immunoblotting; Male; Mitochondria; Piperazines; Probability; Pyrimidines; Sensitivity and Specificity; Tumor Cells, Cultured

2004
Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.
    Journal of the American Society of Nephrology : JASN, 2005, Volume: 16, Issue:2

    Topics: Animals; Apolipoproteins E; Base Sequence; Benzamides; Biopsy, Needle; Diabetic Nephropathies; Disease Models, Animal; Gene Expression Regulation; Imatinib Mesylate; Immunohistochemistry; Kidney Function Tests; Male; Mice; Mice, Knockout; Molecular Sequence Data; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Reference Values; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Transforming Growth Factor beta

2005
Nonaqueous capillary electrophoresis method for the analysis of gleevec and its main metabolite in human urine.
    Journal of chromatography. A, 2005, Mar-11, Volume: 1068, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Electrophoresis, Capillary; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Sensitivity and Specificity; Temperature

2005
High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.
    Blood, 2005, Sep-15, Volume: 106, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Benzamides; Clone Cells; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Frequency; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Sensitivity and Specificity; Treatment Outcome

2005
An amino-acid switch in the BCR-ABL kinase domain modifies sensitivity to imatinib mesylate.
    Leukemia, 2005, Volume: 19, Issue:9

    Topics: Amino Acid Substitution; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutagenesis, Site-Directed; Piperazines; Point Mutation; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity

2005
Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall.
    Histopathology, 2005, Volume: 47, Issue:1

    Topics: Actins; Adult; Aged; Antigens, CD34; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Desmin; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Humans; Imatinib Mesylate; Immunohistochemistry; Keratins; Middle Aged; Muscle, Smooth; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity

2005
Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
    Therapeutic drug monitoring, 2005, Volume: 27, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Stability; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization

2005
Drug discovery: playing dirty.
    Nature, 2005, Oct-13, Volume: 437, Issue:7061

    Topics: Animals; Benzamides; Cardiovascular Diseases; Clinical Trials as Topic; Clozapine; Depression; Drug Approval; Drug Design; Drug Evaluation, Preclinical; Drug Industry; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrimidines; Quinazolines; Sensitivity and Specificity; Substrate Specificity; Therapeutics; United States; United States Food and Drug Administration

2005
BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy?
    Cell cycle (Georgetown, Tex.), 2005, Volume: 4, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Alleles; Benzamides; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Phenotype; Phosphotransferases; Piperazines; Polymerase Chain Reaction; Protein Structure, Tertiary; Pyrimidines; Retrospective Studies; RNA, Messenger; Sensitivity and Specificity

2005
BCRABL transcript detection by quantitative real-time PCR : are correlated results possible from homebrew assays?
    Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology, 2005, Volume: 9, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Transplantation; Genes, abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Middle Aged; Molecular Diagnostic Techniques; Piperazines; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity

2005
The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib.
    Leukemia, 2006, Volume: 20, Issue:4

    Topics: Adult; Aged; Alleles; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sensitivity and Specificity; Sequence Analysis, DNA; Transcription, Genetic

2006
Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.
    Leukemia, 2006, Volume: 20, Issue:4

    Topics: Adolescent; Adult; Aged; Benzamides; Bone Marrow; Chromosome Aberrations; Cloning, Molecular; Cytogenetic Analysis; Disease Progression; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Predictive Value of Tests; Pyrimidines; Reproducibility of Results; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Treatment Outcome

2006
Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan.
    European journal of haematology, 2006, Volume: 76, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diagnosis, Differential; Disease Progression; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome

2006
Identification of transcriptional targets associated with the expression of p210 Bcr-Abl.
    European journal of haematology, 2006, Volume: 76, Issue:5

    Topics: Animals; Benzamides; Cell Line; Cell Proliferation; Cells, Cultured; Chromones; Class I Phosphatidylinositol 3-Kinases; Clone Cells; Fusion Proteins, bcr-abl; Gene Expression Profiling; Glycolysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Morpholines; Oligonucleotide Array Sequence Analysis; Phenotype; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Transcription, Genetic

2006
Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia.
    Leukemia, 2006, Volume: 20, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Cohort Studies; Gene Expression Regulation, Neoplastic; Gene Rearrangement; Genetic Testing; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; Middle Aged; Oncogene Fusion; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Treatment Outcome

2006
hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia.
    Leukemia, 2006, Volume: 20, Issue:4

    Topics: Adolescent; Adult; Aged; Antigens, CD34; Benzamides; Carrier Proteins; Cell Cycle Proteins; Disease Progression; DNA-Binding Proteins; Down-Regulation; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-myc; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA-Binding Proteins; Sensitivity and Specificity; Tankyrases; Telomerase; Telomeric Repeat Binding Protein 1; Telomeric Repeat Binding Protein 2; Transcription, Genetic; Tumor Suppressor Proteins

2006
BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry.
    Leukemia, 2006, Volume: 20, Issue:6

    Topics: Adaptor Proteins, Signal Transducing; Antigens, CD34; Benzamides; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; HL-60 Cells; Humans; Imatinib Mesylate; In Vitro Techniques; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nuclear Proteins; Phosphorylation; Piperazines; Pyrimidines; Sensitivity and Specificity; Tumor Cells, Cultured

2006
Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Apr-01, Volume: 12, Issue:7 Pt 1

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Lactams, Macrocyclic; Leukemia; Piperazines; Pyrimidines; Quinones; Rifabutin; Sensitivity and Specificity; Structure-Activity Relationship; Time Factors; Tumor Cells, Cultured

2006
Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib.
    Haematologica, 2006, Volume: 91, Issue:5

    Topics: Alleles; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Genetic Testing; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation, Missense; Piperazines; Point Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Sensitivity and Specificity; Sequence Analysis, DNA; Time Factors

2006
[The diagnostic and predictive role of kit (CD117)].
    Therapeutische Umschau. Revue therapeutique, 2006, Volume: 63, Issue:4

    Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Genetic Markers; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Mutation; Neoplasms; Piperazines; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sensitivity and Specificity; Signal Transduction

2006
Stability-indicating HPTLC determination of imatinib mesylate in bulk drug and pharmaceutical dosage form.
    Journal of pharmaceutical and biomedical analysis, 2007, Jan-17, Volume: 43, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Calibration; Capsules; Chloroform; Chromatography, Thin Layer; Densitometry; Drug Stability; Guidelines as Topic; Hydrolysis; Imatinib Mesylate; Linear Models; Methanol; Oxidation-Reduction; Piperazines; Powders; Protein Kinase Inhibitors; Pyrimidines; Quality Control; Reproducibility of Results; Sensitivity and Specificity; Silica Gel; Silicon Dioxide; Solvents; Technology, Pharmaceutical; Temperature

2007
Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA.
    Leukemia, 2006, Volume: 20, Issue:11

    Topics: Antineoplastic Agents; Benzamides; Drug Monitoring; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genetic Heterogeneity; Genetic Testing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Plasma; Pyrimidines; Reproducibility of Results; RNA, Messenger; Sensitivity and Specificity

2006
Simultaneous determination of AMN107 and Imatinib (Gleevec, Glivec, STI571) in cultured tumour cells using an isocratic high-performance liquid chromatography procedure with UV detection.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2007, Feb-01, Volume: 846, Issue:1-2

    Topics: Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tumor Cells, Cultured

2007
Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia.
    The Journal of molecular diagnostics : JMD, 2006, Volume: 8, Issue:5

    Topics: Adult; Aged; Alleles; Animals; Benzamides; Cell Line; Female; Genes, ras; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Mastocytosis; Mice; Middle Aged; Mutation; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sensitivity and Specificity

2006
Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient.
    British journal of cancer, 2007, Jan-15, Volume: 96, Issue:1

    Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Chordoma; Disease Progression; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Sensitivity and Specificity

2007
Identification of imatinib mesylate degradation products obtained under stress conditions.
    Journal of pharmaceutical and biomedical analysis, 2007, Apr-11, Volume: 43, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Drug Stability; Hot Temperature; Hydrogen-Ion Concentration; Hydrolysis; Imatinib Mesylate; Mass Spectrometry; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Oxidation-Reduction; Photolysis; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Stress, Mechanical; Temperature; Time Factors; Water

2007
Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography.
    Biomedical chromatography : BMC, 2007, Volume: 21, Issue:7

    Topics: Animals; Benzamides; Calibration; Chromatography, High Pressure Liquid; Female; Humans; Imatinib Mesylate; Male; Mice; Piperazines; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet

2007
An in vitro cytologic assay for evaluation of the KIT signaling pathway in gastrointestinal stromal tumors.
    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2007, Volume: 20, Issue:5

    Topics: Benzamides; Cell Line, Tumor; Cytological Techniques; Drug Resistance, Neoplasm; Evaluation Studies as Topic; Everolimus; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Immunosuppressive Agents; In Vitro Techniques; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sensitivity and Specificity; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases

2007
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Antineoplastic Agents; Benzamides; Disease Progression; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Multivariate Analysis; Neoplasm Metastasis; Piperazines; Positron-Emission Tomography; Protein-Tyrosine Kinases; Pyrimidines; Sensitivity and Specificity; Tomography, X-Ray Computed

2007
We should desist using RECIST, at least in GIST.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Antineoplastic Agents; Benzamides; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Piperazines; Pyrimidines; Recurrence; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome

2007
[Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Terapevticheskii arkhiv, 2007, Volume: 79, Issue:4

    Topics: Adult; Antineoplastic Agents; Benzamides; beta 2-Microglobulin; Biomarkers, Tumor; Bone Marrow; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm, Residual; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity

2007
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
    The Journal of clinical investigation, 2007, Volume: 117, Issue:9

    Topics: Alleles; Amino Acid Motifs; Animals; Benzamides; Cell Line; Dasatinib; Drug Resistance, Neoplasm; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Sensitivity and Specificity; Thiazoles; Valine

2007
Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:11

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzamides; Biomarkers; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Histamine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monitoring, Physiologic; Neoplasm, Residual; Piperazines; Probability; Prognosis; Pyrimidines; Radioimmunoassay; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Statistics, Nonparametric; Survival Analysis; Treatment Outcome

2007
Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:2

    Topics: Administration, Oral; Adult; Aged; Benzamides; Biomarkers; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Heart Failure; Humans; Imatinib Mesylate; Male; Middle Aged; Natriuretic Peptide, Brain; Neoplasm Staging; Peptide Fragments; Piperazines; Probability; Prospective Studies; Pyrimidines; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Statistics, Nonparametric; Troponin T

2008
An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation.
    Leukemia research, 2008, Volume: 32, Issue:6

    Topics: Antineoplastic Agents; Benzamides; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoassay; Immunoprecipitation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Phosphorylation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity

2008
Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
    Journal of clinical pathology, 2008, Volume: 61, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Biopsy, Needle; Chi-Square Distribution; DNA Mutational Analysis; DNA, Neoplasm; Female; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Humans; Imatinib Mesylate; Immunohistochemistry; Isoenzymes; Male; Middle Aged; Mitotic Index; Oligonucleotide Array Sequence Analysis; Piperazines; Proportional Hazards Models; Protein Kinase C; Protein Kinase C-theta; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Risk Assessment; Sensitivity and Specificity; Survival Analysis

2008
Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours.
    Annals of medicine, 2001, Volume: 33, Issue:7

    Topics: Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Sensitivity and Specificity; Treatment Outcome

2001
High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2002, Mar-05, Volume: 768, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Chromatography, Liquid; Humans; Imatinib Mesylate; Mass Spectrometry; Piperazines; Pyrimidines; Reference Standards; Sensitivity and Specificity

2002
Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.
    The Journal of biological chemistry, 2002, Aug-30, Volume: 277, Issue:35

    Topics: Adenosine Triphosphate; Benzamides; Binding Sites; Cloning, Molecular; Enzyme Inhibitors; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Piperazines; Point Mutation; Protein Conformation; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Fusion Proteins; Recombinant Proteins; Sensitivity and Specificity; Substrate Specificity

2002